| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 2007;84:1144-1150
© 2007 The Society of Thoracic Surgeons
a Department of Anesthesiology, German Heart Center Munich, Germany
b Department of Cardiology, General Hospital Munich, Harlaching, Germany
c Department of Anesthesiology, Critical Care and Pain Therapy, Behandlungszentrum Vogtareuth, Germany
d Department of Medical Statistics and Epidemiology, Klinikum Rechts der Isar, Munich, Germany
Accepted for publication May 4, 2007.
* Address correspondence to Dr Dietrich, Winthistr. 4, Munich 80639, Germany (Email: wulf.dietrich{at}t-online.de).
Background: Hypersensitivity reactions to the nonspecific proteinase inhibitor aprotinin may occur. The present study evaluates the incidence of hypersensitivity reactions to aprotinin.
Methods: Data were prospectively collected as part of the institution’s quality assurance program. The database was screened for anaphylactic reactions, especially those against aprotinin. The definition of an allergic reaction was predefined. A severe reaction was definded as hemodynamic instability of more than 10 minutes despite high dosages of vasopressors and inotropic medication.
Results: Of 13,315 cardiac operations, 12,403 were done with aprotinin, with 801 reexposures in 697 patients. Eleven reactions to aprotinin (11 of 11,602; 0.09%, 95% confidence interval: 0.05% to 0.16%) were recorded after primary exposure, of which none was severe, while 12 reactions (12 of 801; 1.5%; 95% confidence interval: 0.86% to 2.6%) occurred after reexposure, of which 5 were severe. All severe reactions were in patients reexposed to aprotinin within 6 months after previous exposure. There was no reaction observed in patients reexposed to aprotinin within 3 days after the last exposure (n = 42). The incidence of hypersensitivity reactions was 4.1%, 1.9%, and 0.4% in the less than 6 months, 6 to 12 months, and more than 12 months reexposure intervals, respectively.
Conclusions: The risk of hypersensitivity reactions is low after primary exposure to aprotinin. This risk after reexposure reaches a maximum between the fourth day and the 30th day after previous exposure and declines considerably after 6 months. Consequently, application of aprotinin carries a high risk between the fourth and the 30th day after previous exposure, and cannot be recommended for the first 6 months, but is justifiable in previously aprotinin-exposed patients with a high risk of bleeding after this interval.
This article has been cited by other articles:
|
|
 |
|
  B. J. Kober, A. M. Scheule, V. Voth, N. Deschner, E. Schmid, and G. Ziemer Anaphylactic Reaction After Systemic Application of Aprotinin Triggered by Aprotinin-Containing Fibrin Sealant Anesth. Analg., August 1, 2008; 107(2): 406 - 409. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Eaton Antifibrinolytic Therapy in Surgery for Congenital Heart Disease Anesth. Analg., April 1, 2008; 106(4): 1087 - 1100. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Shaw, M. Stafford-Smith, W. D. White, B. Phillips-Bute, M. Swaminathan, C. Milano, I. J. Welsby, S. Aronson, J. P. Mathew, E. D. Peterson, et al. The Effect of Aprotinin on Outcome after Coronary-Artery Bypass Grafting N. Engl. J. Med., February 21, 2008; 358(8): 784 - 793. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Smith Invited commentary Ann. Thorac. Surg., October 1, 2007; 84(4): 1150 - 1150. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
